CEPRA proposes TOXICOLOGICAL TEST according to GLP (Good Lab Practice) as required by REACH Regulation 1907/2006 or by GHS.
Thanks to a national and international labs, CEPRA support the company to choose best testing strategy, the best lab and to evaluate results of studies.
Principal TOXICOLOGICAL TEST / STUDIES:
Study |
Guideline |
| Skin irritation / corrosion (in vitro) | OECD 431 – OECD 439 |
| Eye irritation / corrosion (in vitro) | OECD 437 – OECD 492 |
| Skin sensitization – Local Lymph Node Assay – Magnusson / Kligman – Buehler method |
OECD 429 OECD 406, EEC B.6 OECD 406 |
| Bacterial reverse mutation test (Ames-test) | OECD 471- EEC B.13/ 14 |
| Cytogenetic testing in mammalian cells: Chromosome Aberration Test (in vitro) |
OECD 473 EEC B.10 |
| Micronucleus test (in vitro) | OECD 487 EEC B.10 |
| Gene mutation test in mammalian cells: Mouse Lymphoma Assay (in vitro) |
OECD 476 EEC B.17 |
| Acute oral toxicity – Acute Toxic Class Method “ATC” – Fixed dose procedure – Up and down procedure |
OECD 423 OECD 420 OECD 425 |
| Acute inhalation toxicity | OECD 403 |
| Acute dermal toxicity | OECD 402, OECD 434 EEC B.3 |
| Repeated dose toxicity | OECD 40 -EEC B.7 OECD 410 OECD 412 OECD 408 – EEC B.26 OECD 411 OECD 413 OECD 452 |
| Assessment of the toxicokinetic behaviour | OECD 417 |